HPCSA-registeredSAHPRA-authorisedPOPIA-secure

HPCSA-registered doctors on the Docto24 panel — editorial portrait of clinical practitioners who review Section 21 cannabis applications.

Our panel

HPCSA-registered doctors

Every doctor on the Docto24 panel is HPCSA-registered, has Section 21 experience, and prescribes independently. We facilitate the consultation; the clinical decision belongs to the doctor.

Dr. Placeholder A — portrait

Dr. Placeholder A

HPCSA MP0XXXXX

General Practice

Cannabis medicine sits inside primary care — same diligence, same record-keeping, same patient relationship.
Dr. Placeholder B — portrait

Dr. Placeholder B

HPCSA MP0XXXXX

Pain Medicine

For chronic pain that has not responded to first-line therapy, a structured cannabinoid trial deserves consideration.
Dr. Placeholder C — portrait

Dr. Placeholder C

HPCSA MP0XXXXX

Psychiatry

Cannabinoids are an adjunct, not a replacement, for evidence-based psychiatric care. The boundary matters.
Dr. Placeholder D — portrait

Dr. Placeholder D

HPCSA MP0XXXXX

Neurology

In treatment-resistant epilepsy and MS spasticity, the cannabinoid evidence base is now strong enough to discuss seriously.
Dr. Placeholder E — portrait

Dr. Placeholder E

HPCSA MP0XXXXX

Palliative Care

In palliative oncology, symptom relief is the goal. Cannabinoids earn their place when they deliver it.
Dr. Placeholder F — portrait

Dr. Placeholder F

HPCSA MP0XXXXX

Internal Medicine

A complete medication review comes first. Then we talk about whether a Section 21 product fits the picture.

Real names, photos, and HPCSA numbers go live with the public launch. The placeholder cards above represent the actual specialties on our panel. Each doctor’s registration is independently verifiable on the HPCSA register.

How we vet our doctors

Three things we require before a doctor joins the panel

1

HPCSA verification

Every doctor presents a current HPCSA registration in good standing. We verify the registration number directly with the Health Professions Council before adding them to the panel.

2

SAHPRA Section 21 experience

We require demonstrated experience filing Section 21 applications. Doctors who have never filed under Section 21 do not join the panel — there is no learning curve at the patient’s expense.

3

Continuing professional development

Cannabinoid medicine is a moving field. Panel doctors commit to ongoing CPD in cannabinoid pharmacology and the evolving SAHPRA framework, and to participating in our internal case review.

Ready to consult?

Begin the eligibility assessment — we route you to the right specialty automatically.